William L. Herring

RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.

Search Publications

Filter by Year

Filter by Publication Type

Search Results

People get ready! A new generation of Alzheimer's therapies may require new ways to deliver and pay for healthcare

Evaluating elements of the care partner experience in individuals who care for people with Alzheimer's disease across the severity spectrum

Going forward: Potential impact of protein-based COVID-19 vaccination coverage on population outcomes and costs in the United States

Comparative effectiveness and cost-effectiveness of natalizumab and fingolimod in rapidly evolving severe relapsing-remitting multiple sclerosis in the United Kingdom

Use of patient-reported outcomes as key drivers in cost-effectiveness models: A review of UK National Institute for Health and Care excellence Health Technology assessments

Relationships among sickle cell disease complications and their implications for Cost-Effectiveness modeling for therapies with Curative intent

Cost-effectiveness models for Alzheimer's disease and related dementias: IPECAD modeling workshop cross-comparison challenge

Cost-effectiveness of respiratory syncytial virus preventive interventions in children: A model comparison study

Evaluation of emerging NASH therapies: The impact of treatment efficacy profiles on long-term health outcomes

Assessing the cost-effectiveness of the novavax COVID-19 vaccine as a potential booster vaccine option for adults in the United States

Cost-effectiveness of respiratory syncytial virus (RSV) prevention interventions in children: A model comparison study

The relationship between asthma control questionnaire scores and exacerbation risk, resource utilization, and utility values: An analysis from the captain trial

What might have happened: The impact of interrupting entry of innovative drugs on disease outcomes in the United States

Comparative effectiveness and cost-effectiveness of natalizumab and fingolimod in patients with inadequate response to disease-modifying therapies in relapsing-remitting multiple sclerosis in the United Kingdom

Clinical and economic outcomes associated with respiratory syncytial virus vaccination in older adults in the United States

Predicted lifetime health outcomes for aducanumab in patients with early Alzheimer's disease

Estimated public health impact of the recombinant zoster vaccine

Predicted delays in dementia onset for an innovative therapy acting on beta-amyloid in patients with mild cognitive impairment due to Alzheimer's disease

Incremental clinical and economic impact of recombinant zoster vaccination: Real-world data in a budget impact model

The impact of alternative weighting methodologies on cross-indication value-based pricing estimates